GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
Trial Details
- NCT ID
- NCT07489287
- Phase
- PHASE1
- Sponsor
- Roswell Park Cancer Institute
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- GB-5267 - IV only
- GB-5267 -Combined IV and IP Infusion
- Locations (sample)
- Buffalo, New York, United States|42.88645,-78.87837
Key Eligibility Criteria
- At least 18 years of age
- Patients must have epithelial ovarian, peritoneal, or fallopian tube cancer that is confirmed by histology or cytology, with a histopathological di…
- Must have platinum-resistant disease, defined as:
- Progression of disease within 6 months of last platinum-based chemotherapy, OR
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →